Six tyrosine kinase inhibitors (TKIs) are approved to treat BCR::ABL1 positive chronic myeloid leukemia (BCR::ABL1 + CML) [1–6]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.